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Methylation of the fragile X mental retardation 1 (FMR1) exon 1/intron 1 boundary positioned fragile X related
epigenetic element 2 (FREE2), reveals skewed X-chromosome inactivation (XCI) in fragile X syndrome full
mutation (FM: CGG> 200) females. XCI skewing has been also linked to abnormal X-linked gene expression
with the broader clinical impact for sex chromosome aneuploidies (SCAs). In this study, 10 FREE2 CpG sites
were targeted using methylation specific quantitative melt analysis (MS-QMA), including 3 sites that could not
be analysed with previously used EpiTYPER system. The method was applied for detection of skewed XCI in
FM females and in different types of SCA. We tested venous blood and saliva DNA collected from 107 controls
(CGG< 40), and 148 FM and 90 SCA individuals. MS-QMA identified: (i) most SCAs if combined with a Y
chromosome test; (ii) locus-specific XCI skewing towards the hypomethylated state in FM females; and (iii)
skewed XCI towards the hypermethylated state in SCA with 3 or more X chromosomes, and in 5% of the
47,XXY individuals. MS-QMA output also showed significant correlation with the EpiTYPER reference
method in FM males and females (P< 0.0001) and SCAs (P< 0.05). In conclusion, we demonstrate use of
MS-QMA to quantify skewed XCI in two applications with diagnostic utility.
Introduction
Abnormal DNA methylation is an important cause of
aberrant regulation of gene expression of relevance in
a large number of pathologies. For high-throughput,
targeted, locus specific, quantitative methylation
analysis, the Matrix-assisted laser desorption/ionisa-
tion time of flight mass spectrometry (MALDI-TOF
MS) EpiTYPER system has been suggested to have
the greater diagnostic potential than other techniques,
reviewed in: (Refs 1, 2). MALDI-TOF MS is capable
of a technical detection limit as low as 5% and a single
nucleotide resolution of the majority of CpG sites
within amplicons as large as 0.6 kilobases. Its
closest rival is pyrosequencing, which is restricted to
much smaller regions and has lower throughput
(Ref. 1). Recently, we have used the MALDI-TOF
MS based EpiTYPER system to characterise new
epigenetic biomarker regions – Fragile X Related
Epigenetic Elements (Ref. 3). We have shown the
potential clinical utility of these biomarkers in
fragile X syndrome (FXS) diagnostics (Refs 4, 5, 6),
a major inherited condition co-morbid with autistic
behaviours and intellectual disability, reviewed in:
(Ref. 7). We have also validated EpiTYPER analyses
of these biomarkers on DNA derived from venous
blood, saliva, adult and newborn dried blood spots
(Ref. 8), and have shown fragile X mental retardation
1 (FMR1) full mutation (FM) expansions in females
(FM: >200 CGG triplet repeats) to be significantly
associated with skewed X-inactivation. This how-
ever, was not the case for females with FMR1 pre-
mutation expansions (PM: 55–199 repeats) (Ref. 6).
We have also demonstrated that these analyses are pre-
dictive of cognitive impairment in FXS males and
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females (Ref. 4), and can be used to detect sex
chromosome aneuploidies (SCAs) when combined
with a test for sex determining region Y (SRY) copy
number (Ref. 8).
However, a major limitation of MALDI-TOF MS is
that it requires specialised training and proprietary
equipment (Refs 2, 9), which is not available in most
molecular diagnostic laboratories. Another limitation
is that of the 10 CpG biomarker sites within the
fragile X related epigenetic element 2 (FREE2) ampli-
con, the EpiTYPER approach cannot analyse three sites
because they cluster as one fragment, which is too big
in size (Dalton) to be captured within the mass spec-
trum. For this reason, we have developed a low-cost,
high-throughput real-time polymerase chain reaction
(PCR) and high resolution melt (HRM) based
method for quantitative methylation analysis, which
we have named methylation specific – quantitative
melt analysis (MS-QMA). Since the MS-QMA does
not rely on DNA fragmentation, it can be used to
analyse methylation of all CpG sites within the
FREE2 amplicon.
There are a number of published HRM based
methods developed for quantitative methylation
analysis for locus specific (Refs 10, 11, 12, 13) or
genome wide (Ref. 14) applications, each with advan-
tages and limitations for their specific applications.
However, one common feature between all of these
is use of methylation standards generated from
unmethylated samples spiked at different ratios with
artificially methylated DNA to derive in different
ways methylation percentage for the unknown
samples. An important distinction between these
methods and MS-QMA is that MS-QMA uses a
real-time PCR based internal filter process on serially
diluted bisulphite converted DNA to ‘clean’ the data
prior to a methylation value being derived. Although,
we have found that this filter process is essential for
the applications described in this study, this was not
performed in previously described quantitative
HRM methods, which were primarily developed for
assessments in the low methylation range in cancer
diagnostics (Refs 10, 11, 12, 13). The lack of a filter-
ing/quality control process post-conversion could
also be also the reason quantitative HRM has had
limited applications for poor quality DNA samples,
with none being applied to saliva DNA or archival
dried blood spots (Refs 15, 16).
We have used this method to detect FM males
and females using venous blood and newborn dried
blood spot samples (Ref. 17). However, MS-QMA
detection of skewed X-chromosome inactivation
(XCI) in different forms of SCA, and in FM
females, has not been previously examined. In this
study, using a larger cohort, we have compared MS-
QMA performance with that of the EpiTYPER
system for both saliva and venous blood for these
applications as well as for methylation analysis of
FM males.
Materials and methods
Participants
The patient cohort comprised 245 DNA from venous
blood, and 100 saliva DNA samples, with the partici-
pants’ age range between birth and 82 years. Of
these, 90 samples were from individuals with a SCA
or an SRY translocation, 148 were from FM carriers
(males and females with a FM allele) and 107 were
from controls (with each subgroup and participant
age range described in online Supplementary Table 1
for saliva and blood DNA, respectively, with no indivi-
duals providing both saliva and blood DNA for this
study). EpiTYPER system analysis of all of the
samples included in this study has been performed as
part of our previous studies (Refs 6, 8). The majority
of the samples included in this study were collected as
part of FXS cascade testing and routine molecular
microarray testing through Victorian Clinical Genetics
Services (VCGS) and the Greenwood Genetic Center
as described previously (Ref. 8). They included 33
venous blood and four saliva DNA samples from
SCAs. All of these samples were de-identified before
use in this study. Fifty-three additional SCA individuals
who provided saliva DNA were recruited across
Australia as part of another study (Ref. 18). An addition-
al 51 FM blood samples collected from carriers were
recruited through the VCGS and the M.I.N.D.
Institute, University of California at Davis Medical
Center, Sacramento, from families seen at the Fragile
X Treatment and Research Center through a collabora-
tive Genotype-Phenotype NICHD funded study. The
study was approved by the Royal Children’s Hospital
and Southern Health and Monash University Human
Research Ethics Committees, both from Victoria,
Australia, and by the Institutional Review Board of the
University of California at Davis.
Molecular studies
Sample processing. Venous blood samples of 3–10 ml
were collected in Ethylenediaminetetraacetic acid
(EDTA)-treated tubes. DNA was extracted using
NucleoSpin®Tissue genomic DNA extraction kit, as
per manufacturer’s instructions (MACHEREY-NAGEL
GmbH & Co. KG, Düren, Germany); 2 ml saliva
samples were collected using the Oragene® DNA Self-
Collection Kit (DNA Genotek Inc., Ottawa,Canada)
and isolated as per manufacturer’s instructions.
CGG sizing, methylation using Southern blot and SRY
real-time PCR. For venous blood and saliva DNA, the
processing of DNA samples and assessment of CGG
repeat size (with precision of +/− one repeat) was
conducted using a validated PCR amplification assay
(Ref. 19). CGG repeat sizing and methylation of the
FMR1 CpG island restriction sites of all samples
greater than 55 repeats was also performed using a
methylation sensitive Southern blot procedure with
appropriate normal and abnormal controls, as
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previously described (Ref. 20). FREE2 methylation
analysis using the Sequenom EpiTYPER system for
each sample was performed in quadruplicate, giving
four separate methylation output ratios (MOR), which
were averaged to take account for technical variation
resulting from bisulphite conversion, PCR and mass
cleave reactions, as previously described (Refs 3, 5).
For SCA samples and control males and females, the
SRY copy number was determined using the real-
time PCR relative standard curve method, normalised
to β-globin, as described in (Ref. 8).
MS-QMA. Blood and saliva DNA extracts were treated
with sodium bisulphite using EZ-96 DNA Methylation-
Gold™ (Zymo Research, Irvine, CA) as previously
described (Ref. 8). The 96 well plates of converted
DNA were serially diluted four times in water with all
dilutions transferred into a 384 well format for MS-
QMA analysis of FREE2 biomarkers performed as previ-
ously described (Ref. 17). Briefly, real-time PCR portion
of MS-QMA utilised MeltDoctor™ high-resolution melt
reagents in 10 ul reactions as per manufacturer’s instruc-
tions (Life technologies, Foster City, CA), using primers
targeting specific CpG sites within the FREE2 region,
as described in (Ref. 17). The ViiA™ 7 Real-Time PCR
System (Life technologies, Foster City, CA) was used
for real-time PCR with 65°C the annealing temperature
ran for 40 cycles. The dynamic linear range was deter-
mined to be between 0.05–10 ng/μl from the standard
curve using a series of doubling dilutions of a converted
DNA standard from a control lymphoblast cell line.
The HRM step followed the real-time PCR for sample
within this dynamic linear range in closed tube format.
During the HRM step as strands separated the
MeltDoctor™ dye was released and detected by the
system. The HRM Software Module for ViiA™ 7
System was then used to extract arbitrary fluorescence
units (AFU) at 78°C (the temperature that provided the
greatest difference in AFU between methylated and
unmethylated products). This AFU value was then used
to derive methylation ratio for unknown samples from
an HRM methylation standard curve co-run on each
384 well plate. This methylation curve was plotted from
AFU values over expected methylation of spiked
lymphoblast DNA samples from a control male with
completely unmethylated FREE2 and a FXS male
with 100% methylated FREE2.
MS-QMA quality control (QC) and mean methylation
ratio (MR). The AFU values from HRM of the standard
curve samples for real-time PCR were used to deter-
mine the quality control range. The quality control
range represented HRM values where AFU output at
78°C melt did not change between dilutions. The
AFU values for the unknown samples with high
DNA quality post conversion had to be within this
range for their MR values to pass QC filter process.
From the four dilutions of each bisulphite conversed
DNA sample being assayed, there would be a
minimum of 2 and a maximum of 4 MR values that
pass QC. The final MR value per sample would then
be determined as a mean of all MR from bisulphite con-
verted DNA dilutions for that sample that passed QC.
Data analysis
The relationship between MALDI-TOF MS CpG10-12
methylation as a predictor and MS-QMA MR as an
outcome variable was assessed using simple linear
regression analysis. Testing for normality distribution
of the methylation ratio for pooled data and each sub-
sample was conducted using Shapiro–Wilk test at the
significance level of P= 0.05. Depending on results
of this test for the inter-group comparisons, either
two-sample t-test for the means was used, if the data
were normally distributed, or nonparametric Mann–
Whitney test for median was used, if the data were
not normally distributed. All analyses were conducted
using the publicly available R statistical computing
package (R Development Core Team 2007 R: A
Language and Environment for Statistical Computing,
R Foundation for Statistical Computing, Vienna,
Austria, ISBN 3-900051-07-0. URL: http://www.r-
project.org/; date of accession: February 19, 2009).
Results
MS-QMA analysis of saliva and venous blood DNA for
detection of SCAs
In our earlier study using venous blood samples we
have shown that the MS-QMA threshold range
between 0.39 and 0.41 MR provided sensitivity and
specificity approaching 100% for detection of FM
females with verbal IQ (VIQ) impairment (<70)
(Ref. 17). The threshold of 0.37 MR was the
maximum value of the female healthy control range
as well as the optimal for detection of FM females
with performance IQ (PIQ) and full scale IQ (FSIQ)
impairment (<70). Consistent with this, both blood
and saliva DNA from female controls showed MR
below the 0.37 maximum control value. Three out of
57 XXY saliva samples (5%) showed MS-QMA MR
above the 0.37 MR threshold. Being above the methy-
lation maximum in control females, representing
expected range values for ‘normal pattern’ of X-inacti-
vation for 2 X chromosomes in one cell, it suggests that
these 5% of XXY samples have extremely skewed X-
inactivation in saliva, or presence of cells with a third
X chromosome not detected by microarray technology
(Fig. 1a). It is also of interest that the saliva DNA of the
FXS affected males had MS-QMA MR values well
above these thresholds, whereas for the PM/FM
mosaic group one male showed an MR of 0.37.
For venous blood DNA, only samples with three or
more copies of X chromosome showed MS-QMA MR
above the 0.37 threshold (Fig. 2a). As with our previous
FREE2 methylation analyses using the EpiTYPER
system (Ref. 8), the 47,XXX and 49,XXXXY groups
showed MS-QMA MR significantly above those of
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MS-QMA and SRY copy number analysis in saliva DNA samples
from control males and females and individuals with a sex
chromosome aneuploidy
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FIGURE 1.
MS-QMA and SRY copy number analysis in saliva DNA samples from control males and females and individuals with a sex chromosome
aneuploidy. There were 13 46,XY control males (<40 CGGs); 27 46,XX control females (<40 CGGs); 36 47,XXY Klinefelter syndrome
males (confirmed by microarray analysis); 12 47,XXY treated as Klinefelter syndrome males (confirmed by androgen receptor methylation ana-
lysis and androgen receptor CAG repeat length heterozygocity; no karyotype available); 5 mosaics for 46,XY/47,XXY (confirmed by micro-
array analysis); and 4 46,XX males with an SRY translocation (confirmed by microarray analysis), 2 PM/FM size mosaic males, 1 FM male (a)
The MR values were determined using MS-QMA; (b) The SRY/β-globin copy number ratios were determined using real-time PCR relative
standard curve method. Note: the red broken line represents the maximum value of the female control group; the black broken line represents
the optimal threshold value for detection of presence of one or more copies of Y chromosome. FM, full mutation; MR, methylation ratio; MS-
QMA, methylation specific quantitative melt analysis; PCR, polymerase chain reaction; PM/FM, permutation/full mutation; SRY, sex deter-
mining region Y.
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MS-QMA and SRY copy number analysis in blood DNA samples
from control males and females and individuals with a sex
chromosome aneuploidy
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FIGURE 2.
MS-QMA and SRY copy number analysis in blood DNA samples from control males and females and individuals with a sex chromosome
aneuploidy. There were 19 46,XY control males (<40 CGGs); 48 46,XX control females (<40 CGGs); 4 47,XXY Klinefelter syndrome
males; 10 45,X Turners syndrome females; 8 47,XXX females; 4 47,XYY males; 1 48,XXYY/47,XXY mosaic male; 2 48,XXXY males;
and 4 49,XXXXY males. All were confirmed by microarray analysis. (a) The MR values determined using MS-QMA; (b) The SRY / β-
globin copy number ratios determined using real-time PCR relative standard curve method. Note: the red broken line represent the
maximum value of the female control group; the black broken line is the threshold value that optimally separates samples with one or more
copies of the Y chromosome. Red arrow highlights a 45,X sample with SRY/β-globin ratio above the positive threshold of 0.1. Because
the Y chromosome was not detected using microarray analysis in this sample and SRY FISH could not be performed because of blood
sample unavailability, this result may be either a false positive or a true positive where real-time PCR may be a more sensitive approach for
detection of low level mosaicism. For comparisons with 46,XY controls ### P< 0.001 for SRY cioy munber and 46,XX controls ∗∗∗ P<
0.001 for MS-QMA MR, nonparametric Mann–Whitney test for median was used. FISH, fluorescence in situ hybridisation; MR, methylation
ratio; MS-QMA, methylation specific quantitative melt analysis; PCR, polymerase chain reaction; SRY, sex determining region Y.
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female controls. As expected, saliva and venous blood
DNA samples with a Y chromosome according to previ-
ous laboratory testing also showed ∼1 copy of SRY,
whereas samples with two ormore copies of aY chromo-
some showed SRY copy number between 1.5 and 2 (Figs
1b and 2b). The only exceptionwas one 45,X sample that
consistently showed SRY/β-globin ratio above the posi-
tive threshold of 0.1 (Fig. 2b). Because the Y chromo-
some was not detected using microarray analysis in this
sample and SRY fluorescence in situ hybridisation
(FISH) could not be performed because of blood
sample unavailability, this result may be either a false
positive or a true positive where real-time PCR may be
a more sensitive approach for detection of low level
mosaicism.
Detection of skewed X-inactivation and the comparison
with the EpiTYPER system
Herewe have explored the relationship between X-inacti-
vation and FREE2MS-QMAMR in a larger sample than
was previously analysed with the EpiTYPER system
(Ref. 6). Despite the differences in assay design, there
was significant correlation between the two assays in
blood and saliva of female controls, blood of FM males
and females and in saliva of 47,XXY individuals
(Table 1). The distribution of the MR values in venous
blood DNA for both assays was almost identical in FM
females. It showed clear skewing towards the unmethy-
lated state from the distributions expected if the X-inacti-
vation were random at this locus (Fig. 3; bell shaped
curve). For both assays,methylation in FMmaleswas sig-
nificantly elevated compared with that in FM females.
The only difference between the two assays was evident
in FMmales where for the EpiTYPER system the methy-
lation ratio was skewed towards 1, whereas the FREE2
MS-QMA MR was normally distributed in the same
samples, with the top and bottom tails of distribution at
∼1 and 0.5, respectively.
Discussion
In this study FREE2 MS-QMA identified all SCAs
when combined with an SRY test. It also detected
both locus-specific skewing towards the hypomethy-
lated state, as is apparent in FM females, and skewed
X-inactivation towards the hypermethylated state for
the whole X-chromosome, as with SCAs with three
or more X chromosomes. Continuing from the previous
observations with venous blood and saliva DNAwhere
the EpiTYPER system FREE2 CpG10-12 methylation
analysis detected skewed X-inactivation (Ref. 6) and
identified SCAs when combined with SRY analysis
(Ref. 8), we assessed the performance of MS-QMA
for detection of these same abnormalities. We found
that as with the EpiTYPER system, when combined
with the SRY analysis at the MR threshold of 0.1,
MS-QMA identified SCAs with specificity and sensi-
tivity approaching 100%. However, without the SRY
analysis and at the maximum control female methyla-
tion threshold of 0.37, MS-QMA could not detect the
vast majority of SCAs using either venous blood or
saliva DNA. The exceptions were samples with three
or more X chromosomes that showed median MR sig-
nificantly higher than the median of the female control
range. Because in these samples only one X chromo-
some remains active, with more X chromosomes in
the ‘DNA mix’, skewing towards the hypermethylated
state was observed as be expected, using MS-QMA in
this study and the EpiTYPER system previously
(Ref. 6).
In the FMR1 locus specific context, as with the
EpiTYPER system results, the MS-QMA MR control
range was lower than the expected value of 0.5, with
∼0.4 being the maximum control value, and ∼0.3
being the mean value. This is an unusual feature of
the FREE2 region that we have reported earlier using
the EpiTYPER system, but could not explain
(Ref. 6). However, we have suggested that in part
because of this property we could identify cognitively
impaired hypermethylated FM females more readily
than the analysis of CpG island region targeted by
Southern blot as part of the standard diagnostic proto-
col (Ref. 4).
In this study, MS-QMA also showed clear skewing
towards the unmethylated state from the distributions
TABLE 1.
SIMPLE LINEAR REGRESSION ANALYSIS BETWEEN FRAGILE X RELATED EPIGENETIC ELEMENT 2 (FREE2)
METHYLATION ASSESSED USING MATRIX-ASSISTED LASER DESORPTION/IONISATION TIME OF FLIGHT
MASSSPECTROMETRY (MALDI-TOF MS) – THE PREDICTOR VARIABLE, AND METHYLATION SPECIFIC QUANTITATIVE
MELT ANALYSIS (MS-QMA) – THE OUTCOME VARIABLE, IN VENOUS BLOOD AND SALIVA DNA.
Venous blood DNA Saliva DNA
n Coef± SE R2 n Coef± SE R2
♂ controls 17 0.125± 0.340 0.01 13 −0.500± 1.158 0.02
♀ controls 86 0.256± 0.115∗ 0.06 26 0.440± 0.208∗ 0.16
♂ FM 49 0.559± 0.069∗∗∗ 0.58 … … …
♀ FM 95 1.040± 0.073∗∗∗ 0.69 … … …
47,XXY … … … 47 0.330± 0.130∗ 0.12
FM, full mutation
n represents sample size; Coef. represents regression coefficient; SE represents standard errors
Note: Regression results are presented for groups with n> 10; ∗P< 0.05; ∗∗P< 0.01; ∗∗∗P< 0.001.
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expected if the X-inactivation were random in FM
females at this locus. Specifically, if the X-inactivation
were random, one would expect the higher tail of the
MR distribution to be at 1, representing all cells
having the normal size allele on the inactive X and
the methylated FM allele on the active X. The lower
tail of the distribution would then be 0.5 MR with all
cells having the FM alleles on the inactive X and
normal cell alleles on the active X. In contrast, the
upper tail for both the MS-QMA and EpiTYPER
system results was at ∼0.7 MR with the lower
tail at ∼0. 2MR, demonstrating skewing towards the
unmethylated state. Because in FM males more than
half of the samples showed MR values between 0.7
and 1 MR using either method, the lack of any FM
female results with MR values above 0.7 cannot be
considered to be a result of technical bias associated
with the MS-QMA assay. The most likely explanation
for this is biological, possibly in vivo selection for cells
at the lower tail of the MR distribution that express
Fragile X Mental Retardation Protein (FMRP)
(Ref. 6). This is also consistent with the previous
reports of FM females being generally less severely
affected than FM males, because of the residual
FMR1 activity (Ref. 21).
It is also interesting to note that for FM males with
100% methylation at the FMR1 CpG island (shown
on Southern blot), both MS-QMA and the Epityper
system find methylation of FMR1 intron 1 between
60 and 100%. This suggests that methylation mosai-
cism between different CpG sites in FM males may
be more common than previously thought, and this
may relate to the wide spectrum of clinical phenotypes
(other than severe cognitive impairment) found in FM
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FIGURE 3.
FREE2 methylation comparisons between 50 FM males and 95 FM females assessed with MS-QMA and MALDI-TOF MS MS-QMA targets
seven CpG sites within FMR1 intron 1 including CpG10-12 and three sites within exon 1; whereas MALDI-TOFMS CpG10-12 MOR is spe-
cific only for methylation of CpG10-12. Note: all comparisons between FM males and FM females showed P< 0.001; ∗∗∗ comparisons for
MS-QMA mean values, with two-sample t-test used as the data were normally distributed; ### comparison for MALDI-TOF MS between
median values of the FM groups, with nonparametric Mann–Whitney test used because of the data not being normally distributed. The bell
shaped curve represents the expected normal distribution for the FM females methylation values if the X-inactivation at the locus were
random, with mean methylation ratio of 0.75, the higher tail of distribution at 1 and the lower tail of distribution at 0.5. FM, full mutation;
FMR1, Fragile X mental retardation 1; FREE2, fragile X related epigenetic element 2; MALDI-TOF MS, Matrix-assisted laser desorption/ion-
isation time of flight mass spectrometry; MS-QMA, methylation specific quantitative melt analysis; MOR, methylation output ratio.
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males. It also suggests that the diagnostic classification
of methylation mosaicism in FXS needs to be re-
defined to include methylation of more than just a
few restriction sites targeted by Southern blot.
Comparisons with other HRM based methods for
quantitative methylation analysis
In the context of FXS we are aware of only two
methods utilising HRM (Refs 22, 23) with no publica-
tions on HRM applications for detection of SCAs and
XCI. Furthermore, previous methods utilising HRM
for FXS specific methylation analysis of FMR1
alleles were only applied to venous blood and not
saliva DNA (Refs 22, 23). Although these HRM
methods worked as expected to identify FM males
and in spiked samples using mixtures of methylated
and unmethylated DNA, generating melting peak
standard curves, they did not provide quantitative infor-
mation that could be used to effectively differentiate
FXS females with FM from normal size control and
PM carrier females. This could be either because the
HRM assays targeted different biomarker sites to
FREE2, and methylation of these other sites was too
variable in the female control methylation range,
and/or because the technical variation in quantitative
methylation was too great in this intermediate methyla-
tion range.
To overcome the technical limitation of quantitative
HRM for detection of FXS FM females, we found that
inter and intra run methylation ratio variation has to be
∼5% in the methylation range between 30 and 60%.
We have achieved this using a quality control filter
process involving quantitative real-time PCR analysis
of serial dilutions after bisulphite conversion. We
hypothesise that by diluting the converted samples
we were also diluting out the impurities which could
interfere with the downstream quantitative HRM
assessment at any specific melting temperature. This
procedure minimised the ‘noise’ that was otherwise
associated with the downstream HRM based methyla-
tion assessment. Without these serial dilutions and
the filter process described here, the HRM AFU
values could not be used to differentiate FXS FM
females from the controls, or detect skewed X-inactiva-
tion in blood and saliva.
In summary, we have demonstrated the more imme-
diate applications of MS-QMA for the detection of
skewed XCI at the FMR1 locus and in different types
of SCA. However, the method has potential for any
application where quantitative detection of even small
changes in the genomic position and the amount of
locus specific methylation is of diagnostic or prognos-
tic significance because of mosaicism in the methyla-
tion state within and between different cell types
(Ref. 3). These may include monogenic disorders
such as Rett Syndrome (Ref. 24), trinucleotide disor-
ders such as Friedreich ataxia and myotonic dystrophy
(Refs 3, 25, 26, 27), imprinting disorders such as
Angelman, Prader-Willi and Beckwith-Wiedemann
Syndromes (Ref. 28), disorders related to more
general skewed XCI (Refs 29, 30), as well as somatic
genetic disorders such as cancer (Refs 1, 2).
Supplementary material
To view supplementary material for this article, please
visit http://dx.doi.org/10.1017/erm.2015.11.
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